Dyne Therapeutics, Inc. (DYN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $15.30
- As of
Kresmion compiles this page from DYN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Dyne Therapeutics, Inc. (DYN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full DYN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DYN on one page. Preview it with sample data, then open it live with a free account.
Preview the DYN dossierActive signals for DYN
- highinsider_cluster_sell
4 insiders at DYN sold $65.4M this week
- highCONSENSUS_BUY
3 tracked funds increased DYN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +66% to DYN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +5858% to DYN (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +172% to DYN (2026Q2)
FREE, NO ACCOUNT
Every signal on DYN, as it fires
You are seeing 5 of 10 signals recorded on DYN since 2026-05-16.
The five above landed across 2 days. The other 5 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DYN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 26818M108 · 2026Q2 | $25.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 26818M108 · 2026Q2 | $9.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 26818M108 · 2026Q2 | $8M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 26818M108 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 26818M108 · 2026Q2 | $315K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DYN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
DYN against its peers
DYN's return on equity of -45.9% ranks in the 35th percentile of 23 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | DYN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 101M | n/a | 18 |
| Operating margin | n/a | -125.6% | n/a | 16 |
| Net margin | n/a | -54.6% | n/a | 16 |
| Return on equity | -45.9% | -28.7% | 35 | 23 |
| 1 year | 9.1% | 26.2% | 39 | 18 |
Peers (23): DNLI, RCUS, ELVN, CELC, ARQT, GRTX, ACAD, ZLAB, PGEN, IDYA, XENE, ATAI, LEGN, VKTX, VCYT, BEAM, MBX, TLX, NAMS, CPRX, RLAY, TNGX, IRON. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (DYN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow DYN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to DYN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.